Oramed Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company developing oral drug delivery technologies, with its primary focus on an oral insulin capsule designed as an alternative to injectable insulin for treating type 2 diabetes. The company lacks internal manufacturing, sales, and distribution capabilities, pursuing a strategy of seeking strategic partnerships with established pharmaceutical companies to provide commercialization infrastructure and support for clinical trials, while also maintaining a portfolio of equity and debt investments in other biomedical companies and real estate. Revenue generation depends entirely on successfully advancing its drug candidates through regulatory approval, demonstrating safety and efficacy in human trials, achieving manufacturing scale-up, and ultimately gaining market acceptance in a highly competitive biopharmaceutical landscape dominated by larger, better-resourced competitors.